Circulating Immunes Cells, Cytokines and Brain Radiotherapy (CYRAD)

Centre Francois Baclesse

Status

Enrolling

Conditions

Head and Neck Cancer

Treatments

Other: Collection of blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT05082961

2021-A01862-39

Details and patient eligibility

About

Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation.

In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response response after proton therapy (PT) and carbon therapy (CT). The objective of this project is to study the effect of hadrontherapy on resident/circulating inflammation after brain irradiation. brain irradiation. In a first step, the impact of different PT and CT TEL on macrophages (MФ), the most abundant immune cells in malignant solid tumours, will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons will be studied in vivo in rodents and patients. rodent and patient. In this project, we propose to study for the first time the inflammatory response after hadrontherapy in the context of a cephalic tumour. cephalic tumour. These results will allow a better understanding of the biological response response following PT and CT with the aim of optimising RT and potentially and potentially translate these data to the clinic.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients > 18 years
Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated
Surgery for complete tumour resection or with microscopic residue R1
All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma,meningioma other tumours
Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 54 Gy of X-ray photon radiation or equivalent proton radiation.
Patient affiliated to a social security scheme
Signature of the informed consent before any specific procedure related to the study

Exclusion criteria

Macroscopic postoperative tumour residue R2
Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer).
Previous radiotherapy (except brachytherapy of the cervix or prostate)
Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy
Long-term immunosuppressive or corticosteroid therapy
Patient deprived of liberty or under guardianship, protected adult
Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons
Pregnant or breastfeeding woman
Emergency situations